Related Experiment Video
Updated: Jul 27, 2026
08:32
Induction of an Inflammatory Response in Primary Hepatocyte Cultures from Mice
Published on: March 10, 2017
Fibroblast Growth Factor-23 Concentration in Dogs with Chronic Kidney Disease
L M Harjes1, V J Parker1, K Dembek1
1Veterinary Clinical Sciences, The Ohio State University, Columbus, OH.
Journal of Veterinary Internal Medicine
|April 19, 2017
Summary
Fibroblast growth factor-23 (FGF-23) levels rise with chronic kidney disease (CKD) progression in dogs. This biomarker may help understand CKD-mineral bone disorder (CKD-MBD) in canine patients.
Area of Science:
- Veterinary Medicine
- Nephrology
- Endocrinology
Background:
- Chronic kidney disease (CKD) in dogs is linked to mineral and bone disorders (CKD-MBD).
- Fibroblast growth factor-23 (FGF-23) is an emerging biomarker for CKD progression and survival in humans and cats.
- Data on FGF-23 in dogs with CKD is limited.
Purpose of the Study:
- To quantify FGF-23 concentrations in dogs across various CKD stages.
- To investigate the relationship between FGF-23 and CKD-MBD markers like phosphorus and parathyroid hormone (PTH).
- To validate an ELISA assay for canine plasma FGF-23 measurement.
Main Methods:
- A prospective cross-sectional study involving 32 dogs with naturally occurring CKD and 10 healthy controls.
- Plasma FGF-23 concentrations were measured using an FGF-23 ELISA.
- Associations with serum creatinine, phosphorus, calcium, and PTH were analyzed.
Main Results:
- Plasma FGF-23 concentrations significantly increased with CKD severity (IRIS stages).
- Elevated FGF-23 was observed more frequently than hyperparathyroidism or hyperphosphatemia.
- Serum creatinine and phosphorus were the strongest independent predictors of FGF-23 levels.
Conclusions:
- Plasma FGF-23 concentrations increase as canine CKD progresses.
- FGF-23 shows potential as a valuable biomarker for studying CKD-MBD pathophysiology in dogs.
